Skip to main content

Market Overview

Aerie Pharmaceuticals Announces Initiation Of Second Phase 3 Trial For Roclatan


Aerie Pharmaceuticals Inc (NASDAQ: AERI), a clinical-stage pharmaceutical company that focuses on the treatment of glaucoma and other diseases of the eye, announced on Monday that it has successfully began dosing the first patients enrolled in Mercury 2, the company's second Phase 3 registration trial of Roclatan.

Roclatan is a novel, once-daily eye drop that Aerie is testing for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension.

Aerie began its first Phase 3 trial for Roclatan, named Mercury 1, last September. A third Phase 3 trial, named Mercury 3, is scheduled to commence in the first half of 2017 and is intended to be the sole purpose of facilitating regulatory approval and commercialization in Europe.

Related Link: Mead Johnson Details New Production Expansion In China

"We are pleased to have commenced Mercury 2 on schedule, and we currently expect to read out topline 90-day efficacy data for the trial in the second quarter of 2017. Further, the Mercury 1 topline 90-day efficacy readout continues to be on track for the third quarter of 2016. Should both Mercury registration trials be successful, we expect to file the NDA for RoclatanTM in the second half of 2017, approximately one year after we anticipate filing the NDA for RhopressaTM," said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.

Shares of Aerie Pharmaceuticals showed no trades early Monday morning and have plunged more than 60 percent over the past year.


Related Articles (AERI)

View Comments and Join the Discussion!

Posted-In: Aerie Pharmaceuticals Clinical Stage Pharmaceuticals Eye DiseasesBiotech News Health Care Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at